“De novo” psoriasis and relapse of psoriasis induced by dupilumab: three new cases and review of the literature
I Trave, I Salvi, M Burlando, E Cozzani… - Journal of Clinical …, 2023 - mdpi.com
Atopic dermatitis and psoriasis are traditionally considered diseases that cannot coexist,
since they are described as the result of the activation of opposing inflammatory pathways …
since they are described as the result of the activation of opposing inflammatory pathways …
Paradoxical Psoriasis: An Updated Review of Clinical Features, Pathogenesis, and Treatment Options
CA Maronese, M Valenti, C Moltrasio… - Journal of Investigative …, 2024 - Elsevier
The definition of paradoxical psoriasis (PP) encompasses 2 main scenarios, namely,(i) new-
onset psoriasis in patients treated for a different disease and (ii) worsening as well as …
onset psoriasis in patients treated for a different disease and (ii) worsening as well as …
Treatment of severe atopic dermatitis with upadacitinib in clinical practice: short-term efficacy and safety results
JJ Pereyra Rodríguez, P Herranz, I Figueras Nart… - 2022 - rodin.uca.es
Introduction: Death with a functioning graft (DWFG) is the most frequent cause of loss of
kidney transplantation (KT). Objective: To analyze the evolution of the causes of DWFG and …
kidney transplantation (KT). Objective: To analyze the evolution of the causes of DWFG and …
Upadacitinib for the treatment of atopic dermatitis in a spanish cohort—real life: fifty-two–week follow-up results
JJ Pereyra-Rodriguez, P Herranz, I Figuras-Nart… - Dermatitis, 2022 - liebertpub.com
Atopic dermatitis (AD) is a chronic, inflammatory, and pruritic skin disease. Recently,
upadacitinib, a selective JAK-1 inhibitor, has been incorporated for AD treatment. Real …
upadacitinib, a selective JAK-1 inhibitor, has been incorporated for AD treatment. Real …
Development of a clinical algorithm to predict phenotypic switches between atopic dermatitis and psoriasis (the “Flip‐Flop” phenomenon)
S Müller, T Welchowski, M Schmid, L Maintz… - Allergy, 2024 - Wiley Online Library
Background Atopic dermatitis (AD) and psoriasis vulgaris (PV) are almost mutually exclusive
diseases with different immune polarizations, mechanisms and therapeutic targets. Switches …
diseases with different immune polarizations, mechanisms and therapeutic targets. Switches …
Upadacitinib sustained-release tablets for the treatment of chronic refractory gouty arthritis: a case report and literature review
L Yu, W Huang, H Lv, L Jin, W Lei - Frontiers in Medicine, 2024 - frontiersin.org
Background Gouty arthritis (GA) is a crystal-related joint disease caused by the deposition of
monosodium urate (MSU) crystals, directly associated with hyperuricemia resulting from …
monosodium urate (MSU) crystals, directly associated with hyperuricemia resulting from …
[HTML][HTML] Janus Kinase Inhibitors as Successful Treatment Alternative in Dupilumab-Induced Psoriasis
L WeissWeiss, CP Marbet, LB Branca… - Case Reports in …, 2024 - karger.com
Introduction: After the introduction of dupilumab as systemic treatment for atopic dermatitis,
an increasing number of patients have been successfully treated. However, reports of …
an increasing number of patients have been successfully treated. However, reports of …
[HTML][HTML] Upadacitinib as a treatment for co-existent allergic contact dermatitis and psoriasis
PY Ch'en, M Al-Saedy, EJ Song - JAAD Case Reports, 2024 - Elsevier
Atopic dermatitis (AD) and psoriasis have divergent and antagonistic immune mechanisms,
explaining the rarity of the presence of both diseases in the same individual. AD has been …
explaining the rarity of the presence of both diseases in the same individual. AD has been …
IL-19 may aggravate atopic dermatitis by enhancing the role of IL-4/IL-13 in downregulating keratinocyte barrier proteins and upregulating the secretion of …
L Liu, L Wang, L Ge, H Wang, S Feng, L Jiang, P Jiang… - 2022 - researchsquare.com
Atopic dermatitis (AD) is a relapsing inflammatory skin disorder, with characteristic T helper
2 (Th2)-based immune dysregulation and epidermal barrier function defect. In AD …
2 (Th2)-based immune dysregulation and epidermal barrier function defect. In AD …
Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective
A Guglielmo, ML Deotto, L Naldi, G Stinco… - Dermatology …, 2024 - pagepress.org
This comprehensive review offers a detailed look at atopic dermatitis (AD) treatment in Italy,
focusing primarily on the use of biologics and small molecules. In response to advancing …
focusing primarily on the use of biologics and small molecules. In response to advancing …